Evidence map›Paper›PMID 26090994›Full record

ArticlePloS one2015

Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms.

Naoya Tatsumi, Nozomi Hojo, Hiroyuki Sakamoto, Rena Inaba, Nahoko Moriguchi, Keiko Matsuno, Mari Fukuda, Akihide Matsumura, Seiji Hayashi, Soyoko Morimoto and 9 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Novel WT1 Target Genes:BioMed research international · 2020
    Article
  4. Review
  5. Article
  6. WT1 Alternative Splicing: Role of Its Isoforms in Neuroblastoma.Journal of molecular neuroscience : MN · 2017
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Naoya TatsumiDepartment of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan.
Nozomi HojoDepartment of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan.
Hiroyuki SakamotoDepartment of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan.
Rena InabaDepartment of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan.
Nahoko MoriguchiDepartment of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan.
Keiko MatsunoDepartment of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan.
Mari FukudaDepartment of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan.
Akihide MatsumuraDepartment of Surgery, National Hospital Organization, Kinki-Chuo Chest Medical Center, Osaka, Japan.
Seiji HayashiNational Hospital Organization, Kinki-Chuo Chest Medical Center, Osaka, Japan.
Soyoko MorimotoDepartment of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
Jun NakataDepartment of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Osaka, Japan.
Fumihiro FujikiDepartment of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
Sumiyuki NishidaDepartment of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine, Osaka, Japan.
Hiroko NakajimaDepartment of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
Akihiro TsuboiDepartment of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Osaka, Japan.
Yoshihiro OkaDepartment of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
Naoki HosenDepartment of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan.
Haruo SugiyamaDepartment of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan.
Yusuke OjiDepartment of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan.
Osaka University · JPNational Kinki Chuo Hospital for Chest Disease · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Wilms' tumor gene WT1 consists of 10 exons and encodes a zinc finger transcription factor. There are four major WT1 isoforms resulting from alternative splicing at two sites, exon 5 (17AA) and exon 9 (KTS). All major WT1 isoforms are overexpressed in leukemia and solid tumors and play oncogenic roles such as inhibition of apoptosis, and promotion of cell proliferation, migration and invasion. In the present study, a novel alternatively spliced WT1 isoform that had an extended exon 4 (designated as exon 4a) with an additional 153 bp (designated as 4a sequence) at the 3' end was identified and designated as an Ex4a(+)WT1 isoform. The insertion of exon 4a resulted in the introduction of premature translational stop codons in the reading frame in exon 4a and production of C-terminal truncated WT1 proteins lacking zinc finger DNA-binding domain. Overexpression of the truncated Ex4a(+)WT1 isoform inhibited the major WT1-mediated transcriptional activation of anti-apoptotic Bcl-xL gene promoter and induced mitochondrial damage and apoptosis. Conversely, suppression of the Ex4a(+)WT1 isoform by Ex4a-specific siRNA attenuated apoptosis. These results indicated that the Ex4a(+)WT1 isoform exerted dominant negative effects on anti-apoptotic function of major WT1 isoforms. Ex4a(+)WT1 isoform was endogenously expressed as a minor isoform in myeloid leukemia and solid tumor cells and increased regardless of decrease in major WT1 isoforms during apoptosis, suggesting the dominant negative effects on anti-apoptotic function of major WT1 isoforms. These results indicated that Ex4a(+)WT1 isoform had an important physiological function that regulated oncogenic function of major WT1 isoforms.

Indexed as

AnimalsAntibiotics, AntineoplasticApoptosisBase SequenceCloning, MolecularDoxorubicinExonsHaplorhiniHL-60 CellsHumansK562 CellsMembrane Potential, MitochondrialMiceMice, Inbred C57BLMolecular Sequence DataProtein IsoformsAntibiotics, AntineoplasticDoxorubicinProtein IsoformsRNA, Small InterferingWT1 Proteins

Identifiers

PMID26090994
PMCPMC4474557
OpenAlexW825742739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.